Adalimumab relieves hidradenitis suppurativa

Adalimumab relieves hidradenitis suppurativa
For patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment with once-weekly adalimumab is associated with improvements in pain and inflammation, according to a study published online Dec. 17 in the Annals of Internal Medicine.

(HealthDay)—For patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment with once-weekly adalimumab is associated with improvements in pain and inflammation, according to a study published online Dec. 17 in the Annals of Internal Medicine.

Alexa B. Kimball, M.D., M.P.H., of Harvard Medical School in Boston, and colleagues conducted a parallel, randomized trial involving 154 adult patients with moderate-to-severe HS who did not respond to or who were intolerant of . Patients were allocated to receive placebo or 40 mg adalimumab every week or every other week (EOW) for 16 weeks. All patients were switched to EOW at the start of an open-label 36 week phase, while those who had a suboptimal response could switch to weekly dosing at that point.

After 16 weeks of treatment, the researchers found that a clinical response was achieved in 9.6 percent of those who received EOW adalimumab, 17.6 percent of those who received weekly adalimumab, and 3.9 percent of placebo-treated patients. Serious adverse events were reported in 5.8 percent of EOW, 7.8 percent of weekly, and 3.9 percent of placebo-treated patients. Compared with the placebo group, patients who received weekly adalimumab reported significantly higher improvements in outcomes and pain. Patients who switched from weekly to EOW adalimumab treatment showed a reduction in clinical response.

"This phase 2 dose-ranging study showed evidence of efficacy and tolerability of adalimumab in HS," the authors write. "Inflammation and pain were reduced, and impairment of health-related quality of life and increased."

The study was funded by , the manufacturer of ; several authors disclosed financial ties to Abbott.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Study compares effectiveness of psoriasis treatments

Apr 20, 2012

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of ...

Recommended for you

A better biomonitor for children with asthma

Dec 10, 2014

For the firefighters and rescue workers conducting the rescue and cleanup operations at Ground Zero from September 2001 to May 2002, exposure to hazardous airborne particles led to a disturbing "WTC cough"—obstructed ...

New insight into risk of Ankylosing Spondylitis

Dec 09, 2014

Scientists at the University of Southampton have discovered variations in an enzyme belonging to the immune system that leaves individuals susceptible to Ankylosing Spondylitis.

Novel approach to treating asthma: Neutralize the trigger

Dec 03, 2014

Current asthma treatments can alleviate wheezing, coughing and other symptoms felt by millions of Americans every year, but they don't get to the root cause of the condition. Now, for the first time, scientists ...

Inflammatory discovery sheds new light on skin disease

Dec 02, 2014

Inflammatory skin diseases such as psoriasis may result from abnormal activation of cell death pathways previously believed to suppress inflammation, a surprise finding that could help to develop new ways ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.